Advanced search
Publication Cover
Expert Review of Proteomics Volume 2, 2005 - Issue 3
Submit an article Journal homepage
136
Views
16
CrossRef citations to date
0
Altmetric
Review

Rarity gives a charm: evaluation of trace proteins in plasma and serum

Julia Tait Lathrop Principle Investigator, American Red Cross Holland Laboratory, New Product Discovery, Plasma Derivatives Department, Rockville, MD 20855, USA. [email protected]
,
Timothy K Hayes Director, American Red Cross Holland Laboratory, Analytical Chemistry, Plasma Derivatives Department, Rockville, MD 20855, USA. [email protected]
,
Kevin Carrick Scientist, American Red Cross Holland Laboratory, Protein Characterization, Plasma Derivatives Department, Rockville, MD 20855, USA. [email protected]
&
David J Hammond Executive Director, American Red Cross Holland Laboratory, Plasma Derivatives Department, Rockville, MD 20855, USA. [email protected]
Pages 393-406 | Published online: 09 Jan 2014

References

  • Cohn EJ. Proteins as chemical substances and as biological components. Bull. NY Acad. Med. October, 639–667 (1939).
  • Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845–867 (2002).
  • Lathrop JT, Anderson NL, AndersonNG, Hammond DJ. Therapeutic potential of the plasma proteome. Curr. Opin. Mol. Ther. 5, 250–257 (2003).
  • O’Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell 79, 315–328 (1994).
  • O’Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997).
  • Georgiou HM, Rice GE, Baker MS. Proteomic analysis of human plasma: failure of centrifugal ultrafiltration to remove albumin and other high molecular weight proteins. Proteomics 1, 1503–1506 (2001).
  • Tirumalai RS, Chan Kc, Preto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics 2, 1096–1103 (2003).
  • Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med. 351, 2599–2610 (2004).
  • Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J. Hypertens. 21, 1787–1803 (2003).
  • Cross JT, Benton HP. The roles of interleukin-6 and interleukin-10 in B-cell hyperactivity in systemic lupus erythematosus. Inflamm. Res. 255, 255–261 (1999).
  • Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin-6, and risk of developing Type 2 diabetes mellitus. J. Am. Med. Assoc. 286, 327–334 (2001).
  • Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT. The presence of soluble c-erb-B-2 in saliva and serum among women with breast carcinoma: a prelimary study. Clin. Cancer Res. 6, 2363–2370 (2000).
  • Manshouri T, Do KA, Wang X et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101, 2507–2513 (2003).
  • Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882–5890 (2004).
  • He QY, Lau GK, Zhou Y, Lin MC, Kung HF, Chiu JF. Serum biomarkers of hepatitis B virus infected liver inflammation: a proteomic study. Proteomics 3, 666–674 (2003).
  • Koomen JM, Shih LN, Coombes KR et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin. Cancer Res. 11, 1110–1118 (2005).
  • Ahmed N, Barker G, Oliva KT et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br. J. Cancer 91, 129–140 (2004).
  • Chen JH, Chang YW, Yao CW et al. Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proc. Natl Acad. Sci. USA 101, 17039–17044 (2004).
  • MacGregor I, Drummond O. Immunoassay of human plasma celluar prion protein. Transfusion 41, 1453 (2001).
  • Peden AH, Head MW, Ritchie D, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364, 527–529 (2004).
  • Anderson NG, Gerin JL, Anderson NL. Global screening for human viral pathogens. Emerg. Infect. Dis. 9, 768–773 (2003).
  • Cortese I, Capone S, Tafi R, Grimaldi LM, Nicosia A, Cortese R. Identification of peptides binding to IgG in the CSF of multiple sclerosis patients. Multiple Sclerosis 4, 31–36 (1998).
  • Shoenfeld Y, Rauova L, Gilburd B et al. Efficacy of IVIg affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Internat. Immunol. 14, 1–9 (2002).
  • Le Naour F. Contribution of proteomics to tumor immunology. Proteomics 1, 1295–1302 (2001).
  • Le Naour F, Brichory F, Misek DE, Brechot C, Hanash SM, Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol. Cell. Proteomics 1, 197–203 (2002).
  • Ollert MW, David K, Schmitt C et al. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc. Natl Acad. Sci. USA 93, 4498–4503 (1996).
  • David K, Ollert MW, Vollmert C et al. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblasoma cells by binding to a Mr 260,000 antigen. Cancer Res. 59, 3768–3775 (1999).
  • Fishman P, Bar-Yehuda S, Shoenfeld Y. IVIg to prevent tumor metastases (Review). Int. J. Oncol. 21, 875–880 (2002).
  • Rossi F, Kazatchkine MD. Anti-idotypes against autoantibodies in pooled normal human polyspecific Ig. J. Immunology 143, 4104–4109 (1989).
  • Gilles JG, Saint-Remy JMR. Healthy subjects produce both antiFactor VII and specific anti-idiotype antibodies. J. Clin. Invest. 94, 1496–1505 (1994).
  • Pendergraft WF III, Preston GA, Shah RR et al. Autoimmunity is triggered by cPR-3(105–201), a protein complementary to human autoantigen proteinase-3. Nature Med. 10, 72–79 (2004).
  • Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nature Med. 10, 17–18 (2004).
  • Smith IE. New drugs for breast cancer. Lancet 360, 790–792 (2002).
  • Cheson BD. What is new in lymphoma? CA Cancer J. Clin. 54, 260–272 (2004).
  • Mintz PJ, Kim J, Do KA et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nature Biotechnol. 21, 57–63 (2003).
  • Wetmore BA, Merrick BA. Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol. Pathol. 32, 619–642 (2004).
  • Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckingham RE Jr, Finlayson JS. Hypotension associated with prekallikrein activator (Hagemean-factor fragments) in plasma protein fraction. N. Engl. J. Med. 299, 66–70 (1978).
  • Martin MJ, Muotri A, Gage F, Varki A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nature Med. 11, 228–232 (2005).
  • Lee DC, Stenland CJ, Miller JL et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 41, 449 (2001).
  • Anderson NL, Polanski M, Pieper R et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics 3, 311–326 (2004).
  • Hulmes JD, Bethea D, Ho K et al. An investigation of plasma collection, stabilization, and storage procedures for proteomic analysis of clinical samples. Clin. Proteomics J. 1, 17–31 (2004).
  • Hinerfeld D, Innamorati D, Pirro J, Tam SW. Serum/plasma depletion with chicken IgY antibodies for proteomic analysis from multiple mammalian species. J. Biomol. Techniques 15, 184–190 (2004).
  • Muyldermans S. Single domain camel antibdies: current status. Rev. Mol. Biotechnol. 74, 277–302 (2001).
  • Tam SW, Pirro J, Hinerfeld D. Depletion and fractionation technologies in plasma proteomic analysis. Expert Rev. Proteomics 1, 411–420 (2004).
  • Righetti PG, Castagna A, Herbert B, Taymond F, Rossier JS. Prefractionation techniques in proteome analysis. Proteomics 3, 1397–1407 (2003).
  • Lescuyer P, Hochstrasser DF, Sanchez JC. Comprehensive proteome analysis by chromatographic protein prefractionation. Electrophoresis 25, 1125–1135 (2004).
  • Stasyk T, Huber L. Zooming in: fractionation strategies in proteomics. Proteomics 4, 3704–3716 (2004).
  • Björhall K, Miliotis T, Davidsson P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 4, 1–11 (2004).
  • Fountoulakis M, Takacs M-F, Berndt P, Langen H, Takacs B. Enrichment of low abundance proteins of Escherichia coli by hydroxyapatite chromatography. Electrophoresis 20, 2181–2195 (1999).
  • Karlsson K, Cairns N, Lubec G, Fountoulakis M. Enrichment of human brain proteins by heparin chromatography. Electrophoresis 20, 2970–2976 (1999).
  • Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 249, 386–390 (1990).
  • Furka A, Sebestyen F, Asgedom M, Dibo G. General method for rapid synthesis of multicomponent peptide mixtures. Int. J. Peptide Protein Res. 37, 487–493 (1991).
  • Baumbach GA, Hammond DJ. Protein purification using affinity ligands deduced from peptide libraries. BioPharm. May, 24–35 (1992).
  • Lam KS, Salmon SE, Hersh EM et al. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354, 82–84 (1991).
  • Buettner JA, Dadd CA, Baumbach GA, Masecar BL, Hammond DJ. Chemically derived peptide libraries: a new resin and methodology for lead identification. Int. J. Peptide Protein Res. 47, 70–83 (1996).
  • Hammond DJ, Lathrop JT, Ralston A, Hayes T, Fijalkowska I. Plasma protein binding ligands. American National Red Cross. US10414, 524 (2004).
  • Melkko S, Scheuermann J, Dumelin CE, Neri D. Encoded self-assembling chemical libraries. Nature Biotechnol. 22, 568–574 (2004).
  • Zhou M, Lucas DA, Chan KC et al. An investigation into the human serum ‘interactome’. Electrophoresis 25, 1289–1298 (2004).
  • Anderson L, Anderson NG. High resolution two-dimensional electrophoresis of human plasma proteins. Proc. Natl Acad. Sci. USA 74, 5421–5425 (1977).
  • Görg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4, 3665–3685 (2004).
  • Pieper R, Gatlin CL, Makusky AJ et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 3, 1345–1364 (2003).
  • Zuo X, Speicher DW. Comprehensive analysis of complex proteomes using microscale solution isoeletrofocusing prior to narrow pH range two-dimensional electrophoresis. Proteomics 2, 58–68 (2002).
  • Gelfi C, Vigano A, Ripamonti M et al. A proteomic analysis of changes in prothrombin and plasma proteins associated with the G20210A mutation. Proteomics 4, 2151–2159 (2004).
  • Kwak JY, Ma TZ, Yoo MJ et al. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp. Hematol. 32, 836–842 (2004).
  • Reif OW, Lausch R, Freitag R. High-performance capillary electrophoresis of human serum and plasma proteins. Adv. Chromatog. 34, 2–56 (1994).
  • Moini M. Capillary electrophoresis mass spectrometry and its application to the analysis of biological mixtures. Anal. Bioanal. Chem. 373, 466–480 (2002).
  • Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422, 198–207 (2003).
  • Wu SL, Jardine I, Hancock WS, Karger BL. A new and senstive on-line liquid chromatography/mass spectrometric approach for top-down protein analysis: the comprehensive analysis of human growth hormone in an E. coli lysate using a hybrid linear ion trap/Fourier transform ion cyclotron resonance mass spectrometer. Rapid Commun. Mass Spectrom. 18, 2201–2207 (2004).
  • Lin D, Alpert AJ, Yates JR III. Multidimensional protein identification technology as an effective tool for proteomics. Am. Genomic Proteomic Technol. 1, 38–46 (2001).
  • Brunee C. The ideal mass analyzer: fact or fiction? Int. J. Mass Spectrom. Ion Proc. 76, 125–237 (1987).
  • Yates JR III, Speicher S, Griffin PR, Hunkapiller T. Peptide mass maps: a highly informative approach to protein identification. Anal. Biochem. 214, 397–408 (1993).
  • Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc. Natl Acad. Sci. USA 90, 5011–5015 (1993).
  • Mann M, Hojrup P, Roepstorff P. Use of mass spectrometric molecular weight information to identify proteins in sequence databases. Biol. Mass Spectrom. 22, 338–345 (1993).
  • Pappin DJ, Hojrup P, Bleasby AJ. Rapid identification of proteins by peptide-mass fingerprinting. Curr. Biol. 3, 327–332 (1993).
  • James P, Quadroni M, Carafoli E, Gonnet G. Protein identification by mass profile fingerprinting. Biochem. Biophys. Res. Commun. 195, 58–64 (1993).
  • Eng JK, McCormack AL, Yates JR III. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. Am. Soc. Mass Spectrom. 5, 976–989 (1994).
  • Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18, 2071–2077 (1997).
  • Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnol. 10, 994–999 (1999).
  • Lu Y, Bottari P, Turecek F, Aebersold R, Gelb MH. Absolute quantification of specific proteins in complex mixtures using visible isotope-coded affinity tags. Anal. Chem. 76, 4104–4111 (2004).
  • Bottari P, Aebersold R, Turecek F, Gelb MH. Design and synthesis of visible isotope-coded affinity tags for the absolute quantification of specific proteins in complex mixtures. Bioconjug. Chem. 15, 380–388 (2004).
  • Qian WJ, Monroe ME, Liu T et al. Quantitiative proteome analysis of human plasma following in vivo lipopolysaccharide administration using 16O/18O labeling and the accurate mass and time tag approach. Mol. Cell. Proteomics 4, 700–709 (2005).
  • Wu SL, Choudhary G, Ramstrom M, Bergquist J, Hancock WS. Evaluation of shotgun sequencing for proteomic analysis of human plasma using HPLC coupled with either ion trap or Fourier transform mass spectrometry. J. Proteome Res. 2, 383–393 (2003).
  • Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl Acad. Sci. USA 100, 6940–6945 (2003).
  • Barnidge DR, Goodmanson MK, Klee GG, Muddiman DC. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC/MS using protein cleavage and isotope dilution mass spectrometry. J. Proteome Res. 3, 644–652 (2004).
  • Adam GC, Sorensen EJ, Cravatt BF. Chemical strategies for functional proteomics. Mol. Cell. Proteomics 1, 781–790 (2002).
  • Tyers M, Mann M. From genomics to proteomics. Nature 422, 193–197 (2003).
  • Liu Y, Patricelli MP, Cravatt BF. Activity-based protein profiling: the serine hydrolases. Proc. Natl Acad. Sci. USA 96, 14694–14699 (1999).
  • Adam GC, Sorensen EJ, Cravatt BF. Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype. Nature Biotechnol. 20, 805–809 (2002).
  • MacBeath G. Protein microarrays and proteomics. Nature Genet. 32(Suppl.), 526–532 (2002).
  • Kusnezow W, Hoheisel JD. Solid suppports for microarray immunoassays. J. Mol. Recognit. 16, 165–176 (2003).
  • Wang CC, Huang RP, Sommer M et al. Array-based multiplexed screening and quantitation of human cytokines and chemokines. J. Proteome Res. 1, 337–343 (2002).
  • Huang R, Lin Y, Shi Q et al. Enhanced protein profiling arrays with ELISA-based amplification for high-throughput molecular changes of tumor patients’ plasma. Clin. Cancer Res. 10, 598–609 (2004).
  • Bacarese-Hamilton T, Ardizzoni A, Gray J, Crisanti A. Protein arrays for serodiagnosis of disease. Methods Mol. Biol. 264, 271–283 (2004).
  • Petricoin EF, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst. 94, 1576–1578 (2002).
  • Li J, White N, Zhang Z et al. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. Urol. Oncol. 22, 497–498 (2004).
  • Conrads TP, Fusaro VA, Ross S et al. High-resolution serum proteomic features for ovaian cancer detection. Endocr. Relat. Cancer 11, 163–178 (2004).
  • Shen Y, Tolic N, Masselon C et al. Ultrasensitive proteomics using high-efficiency on-line micro-SPE-nanoLC-nanoESI MS and MS/MS. Anal. Chem. 76, 144–154 (2004).
  • Thulasiraman V, Lin S, Gheorghiu L et al. Reduction of the concentration difference of protein in biological liquids using a library of combinatorial ligands. Electrophoresis (2005) (In Press).
  • Lathrop JT, Sarkar J, McKeague A et al. Functional identification of novel activities – mining the plasma for new therapeutic proteins. Presented at Plasma Products Biotechnology 2003, Curaçao, Netherlands Antilles (2003).
  • Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 306, 640–643 (2004).
  • Yan W, Lee H, Yi EC et al. Systems-based proteomic analysis of the interferon response in human liver cells. Genome Biol. 5, R54 (2004).
  • Reichman J. Help for a healthier 2004. Today Show (2004).
  • Chek E. Running before we can walk? Nature 429, 496–497 (2004).
  • Society of GynecologicOncologists. Society of Gynecologic Oncologists statement regarding OvaCheck™ (2004).
  • National Cancer Institute. Ovarian Cancer (PDQ®): Screening. National Cancer Institute(1998).
  • Lafata JE, Simpkins J, Lamerato L, Poisson L, Divine G, Johnson CC. The economic impact of false-positive cancer screens. Cancer Epidemiol. Biomarkers Prev. 13, 2126–2132 (2004).
  • Petricoin E, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572–577 (2002).
  • Kozak KR, Amneus MW, Pusey SM et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc. Natl Acad. Sci. USA 100, 12343–12348 (2003).
  • Diamandis E. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol. Cell. Proteomics 3, 367–378 (2004).
  • Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 4, 24 (2003).
  • Omenn G. Advancement of biomarker discovery and validation through the HUPO plasma proteome project. Dis. Markers 20, 131–134 (2004).
  • Omenn G. The Human Proteome Organization Plasma Proteome Project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 4, 1235–1240 (2004).
  • Zolg JW, Langen H. How industry is approaching the serch for new diagnostic markers and biomarkers. Mol. Cell. Proteomics 3, 345–354 (2004).
  • Tong W, Link A, Eng JK, Yates JR III. Identification of proteins in complexes by solid-phase microextraction/multistep elution/capillary electrophoresis/tandem mass spectrometry. Anal. Chem. 71, 2270–2278 (1999).
  • Harper RG, Workman SR, Schuetzner S, Timperman AT, Sutton JN. Low-molecular-weight human serum proteome using ultrafiltration, isoelectric focusing, and mass spectrometry. Electrophoresis 25, 1299–1306 (2004).
  • World Health Organization. Avian influenza – fact sheet. World Health Organization (2004).

Websites

  • Human Proteome Organization www.HUPO.org (Viewed May 2005)
  • ProMetic Biosystems, Inc. www.prometic.com (Viewed May 2005)
  • Molecular Probes, Inc. www.probes.com (Viewed May 2005)
  • Mascot http://www.matrixscience.com (Viewed May 2005)
  • Protein Prospector http://prospector.ucsf.edu (Viewed May 2005)
  • ProFound http://prowl.rockefeller.edu (Viewed May 2005)
  • NCBinr ftp://ftp.ncbi.nih.gov/blast/db/blastdb.txt (Viewed May 2005)
  • SwissProt http://au.expasy.org/sprot (Viewed May 2005)
  • OWL http://umber.sbs.man.ac.uk/dbbrowser/OWL (Viewed May 2005)
  • MSDB ftp://ftp.ncbi.nih.gov/repository/MSDB/ msdb.nam (Viewed May 2005)
  • Sequest http://fields.scripps.edu/sequest (Viewed May 2005)
  • PepFrag http://prowl.rockefeller.edu/prowl/pepfrag ch.html (Viewed May 2005)
  • Amersham Biosciences www5.amershambiosciences.com (Viewed May 2005)
  • Uniprot www.pir.uniprot.org (Viewed May 2005)
  • International Protein Index www.ebi.ac.uk/IPI/IPIhelp.html (Viewed May 2005)
  • Ciphergen Biosystems, Inc www.ciphergen.com (Viewed May 2005)
  • Institute for Systems Biology www.systemsbiology.org (Viewed May 2005)
  • Clinical Proteomics Research Map www.CPRMap.com (Viewed May 2005)
  • Correlogic Systems, Inc. www.correlogic.com (Viewed May 2005)
  • Plasma Proteome Institute www.plasmaproteome.org (Viewed May 2005)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.